Gene Logic, Abbott strike development deal

Gene Logic has inked a deal with Abbott to study new pathways for a group of experimental therapies that have passed Phase I. The deal gives Gene Logic a schedule of milestone payments for any successful new programs. Gene Logic's Drug Repositioning Program seeks to find alternative indications for drug candidates with good safety records that have been de-prioritized or discontinued in clinical trials. This is the fifth alliance with Big Pharma by Gene Logic.

- see this release on the pact

Suggested Articles

Biogen unveiled full phase 1/2 for a prospect that emerged from a shift in its thinking about treating amyotrophic lateral sclerosis.

It took a little longer than expected, but Biogen’s done it—along with partner Eisai, the Big Biotech has completed an FDA filing for aducanumab.

Gilead is ditching a new avenue of treating hepatitis B as it cuts ties with Precision Biosciences less than two years into their research pact.